Nebenwirkungen · Briumvi
Briumvi 150 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-150185 · Präparat HOS-100264
Table 2 summarises the adverse reactions that have been reported in association with the use of ublituximab. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each System Organ Class and frequency grouping, adverse reactions are presented in order of decreasing frequency.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T16:12:00Z · SHA-256 53c5ab94f9975d70ba11f2528f2ff97b611a29e4dee6edabccf82093c0699947 · Passage 7cebe66d325359ff2955502614d8873251d2b4539d79aa801fb12595f095c04d · Zeichen 171–626 im Abschnitt